Amgen Inc.  (AMGN)
Other Ticker:  

Amgen Inc's



AMGN Sales vs. its Competitors Q2 2022

Comparing the results to its competitors, Amgen Inc reported Total Revenue decrease in the 2 quarter 2022 year on year by 0 %, despite revenue increase by most of its competitors of 13.8 %, recorded in the same quarter.

List of AMGN Competitors

With net margin of 0 % company reported lower profitability than its competitors.

More on AMGN Margin Comparisons

Revenue Growth Comparisons

Net Income Comparison

Amgen Inc. Net Income in the 2 quarter 2022 grew year on year by 183.84 %, faster than average growth of Amgen Inc's competitiors of 34.82 %

<<  More on AMGN Income Comparisons

Amgen Inc's Comment on Competitors and Industry Peers

Certain of our marketed products face — and our product candidates, if approved, are also expected to face — substantial competition. Our products’ competitive positions among other biological and pharmaceutical products may be based on, among other things, safety, efficacy, reliability, availability, patient convenience/delivery devices, price, reimbursement, timing of market entry and patent position and expirations.

Certain of the existing patents on our principal products have recently expired or will expire over the next few years, and we expect to face increasing competition thereafter, including from biosimilars. A biosimilar is another version of a biological product for which marketing approval is sought or has been obtained based on a demonstration that it is “biosimilar” to the original reference product. See Government Regulation. We may also compete against biosimilar or generic versions of our competitors’ products. In the EU, we are facing increasing competition from biosimilars. In the United States after patent expiration, we expect to face greater competition than today, including from manufacturers with biosimilars approved in Europe, which may seek to obtain U.S. approval.

Some of our products compete with each other. For example, Aranesp® and EPOGEN® compete in the United States, primarily in the dialysis setting. Neulasta® competes with NEUPOGEN®, as Neulasta® is administered as a single dose per chemotherapy cycle while NEUPOGEN® requires more frequent dosing. NEUPOGEN® sales have been adversely impacted by conversion to Neulasta®, which we believe is substantially complete.
The introduction of new products, the development of new processes or technologies by competitors or the emergence of new information about existing products may result in increased competition for our marketed products, even for those protected by patents, or in a reduction of the price that we receive from selling our products. In addition, the development of new treatment options or standards of care may reduce the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates. The following table reflects our significant competitors and is not exhaustive.

*Market share is calculated based on total revenue.

AMGN's vs. Competition, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

(in millions of $)
(in millions of $)
(in millions of $)
Amgen Inc. AMGN 121,882.89 32,341.00 6,576.00 24,300
Abbvie Inc. ABBV 254,075 57,349.00 12,646.00 38,500
Abbott Laboratories ABT 177,747 45,548.00 8,554.00 107,000
Enact Holdings Inc. ACT 3,677 -560.22 1,669.95 19,200
Allergan plc AGN 64,063 16,096.20 -2,478.80 10,500
Bristol myers Squibb Company BMY 152,241 47,144.00 6,636.00 30,250
Johnson and Johnson JNJ 444,792 95,588.00 18,366.00 132,200
Eli Lilly And Company LLY 281,217 29,070.70 5,691.60 33,625
Merck and Co. Inc. MRK 220,813 55,716.00 16,592.00 71,000
Pfizer Inc PFE 251,785 101,132.00 29,331.00 88,300
Alexion Pharmaceuticals Inc ALXN 40,625 6,261.60 535.00 3,837
Biogen Inc. BIIB 28,915 10,633.60 1,574.70 9,100
Agile Therapeutics Inc AGRX 1 6.69 -64.12 28
Mylan N v MYL 8,208 16,861.30 266.40 25,000
Teva Pharmaceutical Industries Limited TEVA 8,769 15,433.00 -1,060.00 0
SUBTOTAL 2,058,811.75 528,620.87 104,835.73 592,840

Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

ICGL's Profile

Stock Price

ICGL's Financials

Business Description


Charts & Quotes

ICGL's News


ICGL's Competitors

Customers & Markets

Economic Indicators

ICGL's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071